Lenacapavir injection offers 100% HIV protection to young women

hindustantimes.com

A clinical trial in South Africa and Uganda showed that lenacapavir injection offers total protection against HIV for young women, with a 100% efficiency rate. The trial compared lenacapavir to two other PrEP drugs, Truvada and Descovy. The breakthrough could significantly impact HIV prevention efforts, especially for populations at high risk. The drug's rollout is pending regulatory approvals and WHO recommendations. Price and accessibility are crucial considerations for widespread adoption.


With a significance score of 5.1, this news ranks in the top 1.7% of today's 29139 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: